Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation

Fig. 2

A Volcano plot of differently expressed (FDR < 0.05 ) EVPs between CRLM and BD in the discovery cohort using mass spectrometry. Each dot represents an individual protein. Boxplot analysis of EVP CXCL7 in the discovery cohort (B), and in the internal validation cohort (C) ns: p>0.05,***: p≤0.001, ****: p≤0.0001. p values by Mann-Whitney U test. D Scheme of longitudinal blood sampling before the start of chemotherapy and two weeks after the start of chemotherapy. Imaging by CT-scan was performed before CMT and 3 months (median range: 1 – 9 months) after the start of CMT. (E-G) Three representative cases of patients either with a decrease of EV-bound CXCL7 and partial response (E), or with stable EV-bound CXCL7 and stable disease (F) or with increase of EV-bound CXCL7 and progressive disease (G). H Boxplot analysis of EVP CXCL7 in the longitudinal cohort for chemotherapy respons prediction. CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease. ns: p>0.05,***: p≤0.001, ****: p≤0.0001. p values by Mann-Whitney U test. I: ROC curve analysis for prediction of CR/PR vs PD after completion of first round of chemotherapy.

Back to article page